Background: Induction test of atrial fibrillation (AF) is one of endpoint measures in
| Electrophysiological study
The presence of LA thrombi was excluded by contrast-enhanced computed tomography. When a contrast defect in the left atrial appendage was suspected, we excluded the presence of LA thrombi by transesophageal echocardiography. All patients underwent an electrophysiological study in the fasting state under conscious sedation.
At the beginning of the procedure, a bolus injection of pentazocine 7.5-15 mg and hydroxyzine pamoate 12.5-25 mg was performed. 
| Catheter ablation
We performed PVAI-based ablation in all patients. A 3.5 mm openirrigated-tip ablation catheter was used, and the ablation catheter was irrigated with heparinized saline. Radiofrequency energy was delivered with a maximum temperature setting of 43°C and a power of 20-35 W. We defined successful PVAI as the loss of PV potentials during sinus rhythm or CS pacing (entrance block) and local PV capture without left atrial capture by pacing from a circular mapping catheter or an ablation catheter placed at the PVs just distal to the radiofrequency ablation lesions (exit block).
In cases with documented non-PV triggers after the completion of PVAI, we added ablation targeting the trigger sites and aimed at complete elimination of the AF inducibility from the targeted sites.
Linear ablation or defragmentation or both were also added after PVAI based on the electrophysiological findings in each case.
| Postcatheter ablation pacing protocol
Following completion of ablation procedure, patients underwent a uniform atrial burst pacing protocol from the CS ostium. The atrial burst pacing was performed with 30 beats at an amplitude of 10 V and pulse width of 1 ms; increasing from 240 to 320 ppm in steps of 20 ppm or failure to 1:1 atrial capture. Inducibility of AF/AT was defined as AF/AT lasting ≥5 minutes or as AF/AT of 30 seconds in separate analyses. Induced arrhythmias were pace-terminated or electrically cardioverted to sinus rhythm.
| Follow-up
It was at the discretion of the treating physicians whether previously tolerated antiarrhythmic drugs were restarted/continued or not after the CA.
Patients were seen in our outpatient clinic at least at 1 month, 3 months, 6 months, and 12 months after the procedure. A clinical evaluation and a 12 lead surface ECG recording were performed at each visit. In addition, whenever patients experienced symptoms suggestive of an arrhythmia, they were instructed to visit our outpatient clinic or the referring physician in order to record a 12 lead surface ECG. In cases of patients with permanent pace maker/intracardiac defibrillator, routine device interrogation was also performed to detect asymptomatic arrhythmias. Holter recording (24 hour) was performed at least once during the period of 6-12 months after the procedure by the referring physician. The first 3 months after the procedure were regarded as a blanking period for episodes. Early recurrence of AF (ERAF) was defined as the finding of any atrial tachyarrhythmia lasting >30 seconds during the 3 month blanking period. Arrhythmia recurrence was defined as the detection of AF/AT lasting >30 seconds after a blanking period.
| Statistical analysis
The data are expressed as mean ± standard deviation (SD) for continuous variables and counts and percentages for categorical variables. 
| RE SULTS

| Patient characteristics
A total of 98 patients were enrolled in this study, 77 men (78.6%) and 21 women (21.4%), and age 61 ± 10 years. There were 63 persistent AF patients (64.3%) and 35 long-standing persistent AF patients (35.7%). At 1 year follow-up of CA, 71 patients did not have AF/AT recurrence. We divided the patients into two groups; recurrence group (n = 27, 27.6%) and no-recurrence group (n = 71, 72.4%). Table 1 summarizes the baseline characteristics of these two groups. There were no significant differences in age or comorbidity such as diabetes mellitus, hypertension, and history of congestive heart failure between the two groups. AF type (persistent AF or long-standing persistent AF), left atrial diameter (LAD), left ventricular ejection fraction (LVEF), and biomarkers such as brain natriuretic peptide (BNP), C-reactive protein (CRP) were also comparable between the two groups. The use of antiarrhythmic drugs, beta blockers, and extra-PVAI procedure did not differ between groups. The recurrence group had more female (P = 0.006), structural heart disease (P = 0.07), multiple sessions (P = 0.008), and ERAF (P = 0.003) compared with the no-recurrence group. ERAF was associated with AF/AT recurrence in the 74 patients with 1st session case (P = 0.005), but not in the 24 patients with multiple sessions (P = 0.67). Of note, burst pacing positivity and maximum burst rate that did not induce sustained AF were not correlated with clinical recurrence.
A multivariate analysis revealed that female gender, multiple sessions, and ERAF were significantly associated with long-term AF/AT recurrence during 1 year of follow-up (OR 3.8, 3.5 and 5.3, P = 0.02, P = 0.02 and P = 0.004, respectively) although the sample size of analysis was small for statistical reliance.
Among 98 studied patients, 50 patients (51%) had inducibility of AF/AT by burst pacing at the end of procedure, which was not associated with clinical recurrence. The sensitivity and specificity of burst positivity for clinical recurrence were 55.6% and 50.7%, respectively. The positive predictive value of burst pacing was as low as 30%, whereas the negative predictive value was relatively high as 75% ( Figure 1A ). Among 50 patients with burst pacing positivity,
AT and AF were induced in 13 and 37 patients, respectively. Of 13 patients with induced AT, six patients (46%) had AF/AT recurrence (three AF and three AT). The consistency of the type of arrhythmia was observed in three patients (50%). On the other hand, of 37 patients with induced AF, nine patients (24%) had AF/AT recurrence (eight AF and one AT). The consistency of the type of arrhythmia was highly observed in eight patients (89%). Thus, inducible AT at the end of procedure was associated with an increased risk of recurrent AF/ AT whereas the form of recurrent tachyarrhythmia was not necessarily an AT but an AF.
| Subgroup analysis
We performed subanalyses of the following four categories; en- During 1 year of follow-up, 29 patients did not have AF/AT recurrence. We divided the patients into two groups; recurrence group (n = 11, 27.5%) and no-recurrence group (n = 29, 72.5%). Table 2 summarizes the baseline characteristics of the two groups. There were no significant differences in age, gender or comorbidity such as diabetes mellitus, hypertension, structural heart disease, and history of congestive heart failure between the two groups. AF type (persistent AF or long-standing persistent AF), LAD, LVEF, and biomarkers such as BNP, CRP were also comparable between the two groups.
The use of antiarrhythmic drugs, beta blockers, ERAF, extra-PVAI procedure, and maximum burst rate which did not induce sustained AF did not differ between groups. The recurrence group had more multiple sessions (P = 0.008) and burst pacing positivity (P = 0.07) compared with the no-recurrence group. Table 3 .
| D ISCUSS I ON
| Main findings
The It is noteworthy that most of the studies consistently showed relatively high negative predictive value despite low positive predictive value (Table 4) . Therefore, additional substrate modification after Previous studies reported an issue of reconnections of the PVAI lines in the remote phase, 15, 16 which is not predictable by the response to atrial burst pacing in the acute phase. Reconnection of linear ablation lines in the atria is also not predictable, and these factors constitute critical portion of AF recurrence. In the present study, ERAF was strongly associated with AF/AT recurrence in the overall studied population. ERAF may partly be associated with reconnections of the ablated lines. 17 Interestingly, ERAF was not associated with AF/AT recurrence in the 24 patients with multiple sessions (P = 0.67), which may be attributable to a transient inflammatory effect rather than reconnections of PVAI line in this population.
The existence of non-PV triggers is another important issue, which is also not predictable by the response to atrial burst pacing. In the present study, multiple sessions were associated with AF/AT recurrence. The previous studies indicated the importance of non-PV triggers in multiple session cases. 18 In addition, female gender was Predictive value of atrial burst pacing may also be limited due to methodological reasons. One is the issue of induction reproducibility. As shown in the previous study, 9 there is concern that the AF/ AT inducibility may be a nonspecific response. Indeed, poor reproducibility could be seen in our preliminary data. Furthermore, susceptible atrial pacing site for AF induction may be different among patients whereas CS ostium is the pacing site in this study. 
| Limitations
There were several limitations in our study. First, the study population was relatively small due to the single-center, observational study. Although the sample size confined to persistent AF cases was larger than in previous studies (Table 4) , 6, 7, 9 ,10 the present findings need to be confirmed in multi-center studies. Second, induction protocol and definition of inducibility are different from the previous studies. In the present study, we found that the shorter definition of inducibility increased the negative predictive value while it also increased the false positive rate (Table 3) . It is possible that the results depend on the studied population or conditions. However, a previous study reported almost the same negative predictive value and false positive rate as our results despite different induction protocol and definition of inducibility in which sample size confined to persistent AF was similar to our study. 10 Third, the residual substrates in the atrium were not evaluated quantitatively in the present study. Chang et al reported that the induction positive cases had a lower biatrial voltage compared with the induction negative cases in paroxysmal AF patients. 8 Further studies are needed in order to validate the relationship between low voltage area and induction positivity in persistent AF patients.
| CON CLUS IONS
AF/AT inducibility at the end of ablation session does not predict long-term clinical recurrence in patients with persistent AF. However, it may have a prognostic value especially as a negative predictor in patients with enlarged LA, probably reflecting a successful substrate modification.
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